Professional articles

by EUROIMMUN

Unique panel of bone turnover marker tests

Featured in Practical Patient Care

Bone turnover markers (BTM) support therapy monitoring in osteoporosis and aid in the diagnosis of certain metabolic bone disorders. Euroimmun (part of Revvity) ...

Therapeutic drug monitoring in autoimmune and oncological diseases

Featured in Clinical Laboratory International

Therapeutic drug monitoring (TDM) supports optimized use of biologic therapies in the treatment of immune-mediated inflammatory diseases and some ...

United expertise for ChLIA diagnostics

Featured in Clinical Laboratory International

Automated chemiluminescence immunoassay (ChLIA) systems are nowadays a mainstay for many diagnostic laboratories. Euroimmun has joined forces with ...

Advances in biomarker diagnostics for Alzheimer’s disease

Featured on SelectScience 

Revvity’s Euroimmun shares insights on the role of amyloid-beta, tau, neurofilament and APOE genotype in Alzheimer’s disease diagnostics
The need for early and accurate ...

Diagnostics for resurging vaccine-preventable diseases

Featured on SelectScience 

Explore comprehensive serological & PCR assays for vaccine-preventable disease detection
EUROIMMUN offers an extensive portfolio of serological assays for detection of IgG ...

Bone turnover markers for diagnostics and therapy monitoring

Featured in Clinical Laboratory International

Bone turnover markers (BTMs) provide a non-invasive method to assess bone remodelling – the process by which old bone tissue is removed and replaced. ...

Diagnostics for vaccine- preventable diseases

Featured in Practical Patient Care

Laboratory tests for vaccine-preventable diseases support diagnosis of acute cases and determination of individual immune status. EUROIMMUN offers an extensive ...

APOE genotyping recommended prior to Alzheimer’s therapy

Featured on SelectScience

Carriers of two copies of the APOE ε4 allele have an increased risk of adverse reaction | New disease-modifying drugs are revolutionizing treatment of Alzheimer’s disease ...

Back to top